Life-extending lung cancer treatment recommended for use on the NHS

Dacomitinib has been recommended as a first-line treatment option for people with a type of non-small-cell lung cancer (NSCLC), in new NICE guidance. This once-a-day pill will be available on the NHS for adults with locally advanced or metastatic NSCLC, who have tested positive for the epidermal growth factor receptor (EGFR) mutation. This is a change from the committee’s initial decision which found dacomitinib to not be a cost-effective use of NHS resources. Clinical trial results showed that people who took dacomitinib had longer overall survival rates than those who took gefitinib (34.1 months compared with 26.8 months), a drug